Article
A pilot study of the pharmacodynamic impact of SSRI drug selection and beta-1 receptor genotype (ADRB1) on cardiac vital signs in depressed patients: a novel pharmacogenetic approach.
Psychopharmacology bulletin - 1 Jan 2010
Thomas Kelan L H, Ellingrod Vicki L, Bishop Jeffrey R, Keiser Michael J
Abstract excerpt
OBJECTIVE: The adrenergic beta-1 receptor gene (ADRB1) Ser49Gly and Arg389Gly variants differentially affect blood pressure response to beta-blocker therapy. Binding site prediction results for fluoxetine and paroxetine in a bioinformatics model estimated that each of these particular selective serotonin reuptake inhibitors (SSRIs) have high receptor affinity as an "Adrenergic (beta) Blocker," which was confirmed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.